On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in Massachusetts to use as laboratories to enable R&D functions associated with its expanding portfolio of immunology candidates, including vaccines for COVID-19 and biological products for other disorders.